Publications by authors named "Christopher D Brawley"

Claim this Profile
A
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Nicholas D James, Noel W Clarke, Adrian Cook, Adnan Ali, Alex P Hoyle, Christopher D Brawley

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Christopher D Brawley

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, Christopher D Brawley, Fiona C Ingleby

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali

PLoS Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L Rush, Laura Murphy, Alicia K Morgans, Noel W Clarke, Adrian D Cook, Christopher D Brawley

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Adnan Ali, Alex Hoyle, Áine M Haran, Christopher D Brawley, Adrian Cook

JAMA Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Adnan Ali, Alex P Hoyle, Christopher C Parker, Christopher D Brawley, Adrian Cook

Eur Urol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Alex P Hoyle, Adnan Ali, Nicholas D James, Adrian Cook, Christopher C Parker, Christopher D Brawley

Eur Urol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy for metastatic prostate cancer-Authors' reply.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Mahesh K B Parmar

Lancet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle

Lancet· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis